{"name":"Chiesi Farmaceutici S.p.A.","slug":"chiesi-farmaceutici-s-p-a","ticker":"","exchange":"","domain":"chiesigroup.com","description":"","hq":"Parma","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2023-01-01","label":"Elfabrio first approved","drug":"Elfabrio","drugSlug":"pegunigalsidase-alfa","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":52,"colorKey":"oncology","drugs":[{"name":"Poractant alfa (Curosurf®)","genericName":"Poractant alfa (Curosurf®)","slug":"poractant-alfa-curosurf","indication":"Respiratory distress syndrome (RDS) in premature infants","status":"marketed"},{"name":"Atimos®","genericName":"Atimos®","slug":"atimos","indication":"Chronic obstructive pulmonary disease (COPD) maintenance therapy","status":"marketed"},{"name":"Beclomethasone (BDP)","genericName":"Beclomethasone (BDP)","slug":"beclomethasone-bdp","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"CHF 1535 100/6 NEXT DPI® 2 months","genericName":"CHF 1535 100/6 NEXT DPI® 2 months","slug":"chf-1535-100-6-next-dpi-2-months","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"CHF 1535 100/6 µg","genericName":"CHF 1535 100/6 µg","slug":"chf-1535-100-6-g","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"CHF5993 pMDI with HFA-134a","genericName":"CHF5993 pMDI with HFA-134a","slug":"chf5993-pmdi-with-hfa-134a","indication":"Maintenance treatment of asthma","status":"phase_2"},{"name":"CHF6001 DPI","genericName":"CHF6001 DPI","slug":"chf6001-dpi","indication":"Chronic obstructive pulmonary disease (COPD)","status":"phase_2"},{"name":"Fluticasone plus salmeterol fixed combination","genericName":"Fluticasone plus salmeterol fixed combination","slug":"fluticasone-plus-salmeterol-fixed-combination","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"Formoterol powder 12 µg/unit dose","genericName":"Formoterol powder 12 µg/unit dose","slug":"formoterol-powder-12-g-unit-dose","indication":"Chronic obstructive pulmonary disease (COPD)","status":"phase_3"},{"name":"Foster® NEXThaler® 100/6 µg/unit dose","genericName":"Foster® NEXThaler® 100/6 µg/unit dose","slug":"foster-nexthaler-100-6-g-unit-dose","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"Seretide Accuhaler® 500/50 µg/actuation","genericName":"Seretide Accuhaler® 500/50 µg/actuation","slug":"seretide-accuhaler-500-50-g-actuation","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"BDP DPI 2 months","genericName":"BDP DPI 2 months","slug":"bdp-dpi-2-months","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"BDP DPI and formoterol DPI","genericName":"BDP DPI and formoterol DPI","slug":"bdp-dpi-and-formoterol-dpi","indication":"Asthma maintenance therapy","status":"phase_2"},{"name":"BDP HFA 100 µg pMDI","genericName":"BDP HFA 100 µg pMDI","slug":"bdp-hfa-100-g-pmdi","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"BDP/FF + Tiotropium","genericName":"BDP/FF + Tiotropium","slug":"bdp-ff-tiotropium","indication":"Asthma (maintenance therapy)","status":"phase_3"},{"name":"BDP/FF/GB","genericName":"BDP/FF/GB","slug":"bdp-ff-gb","indication":"Chronic obstructive pulmonary disease (COPD)","status":"phase_3"},{"name":"BDP/Formoterol Next DPI","genericName":"BDP/Formoterol Next DPI","slug":"bdp-formoterol-next-dpi","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"BDP/salbutamol CFC pMDI","genericName":"BDP/salbutamol CFC pMDI","slug":"bdp-salbutamol-cfc-pmdi","indication":"Asthma maintenance and reliever therapy","status":"phase_3"},{"name":"BDP/salbutamol HFA pMDI","genericName":"BDP/salbutamol HFA pMDI","slug":"bdp-salbutamol-hfa-pmdi","indication":"Asthma maintenance and reliever therapy","status":"phase_3"},{"name":"Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium","genericName":"Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium","slug":"beclometasone-dipropionate-formoterol-fumarate-glycopyrronium","indication":"Chronic obstructive pulmonary disease (COPD) maintenance therapy","status":"phase_3"},{"name":"Beclometasone/Formoterol","genericName":"Beclometasone/Formoterol","slug":"beclometasone-formoterol","indication":"Asthma maintenance and reliever therapy","status":"marketed"},{"name":"Beclometasone/Formoterol/Glycopyrrolate","genericName":"Beclometasone/Formoterol/Glycopyrrolate","slug":"beclometasone-formoterol-glycopyrrolate","indication":"Chronic obstructive pulmonary disease (COPD) maintenance treatment","status":"phase_3"},{"name":"Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium","genericName":"Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium","slug":"beclomethasone-dipropionate-formoterol-fumarate-glycopyrronium","indication":"Maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults","status":"phase_3"},{"name":"Beclomethasone dipropionate/Salbutamol combination","genericName":"Beclomethasone dipropionate/Salbutamol combination","slug":"beclomethasone-dipropionate-salbutamol-combination","indication":"Asthma maintenance and reliever therapy","status":"phase_3"},{"name":"Beclomethasone plus formoterol fixed combination","genericName":"Beclomethasone plus formoterol fixed combination","slug":"beclomethasone-plus-formoterol-fixed-combination","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"Budesonide 200 µg plus formoterol 6 µg DPI","genericName":"Budesonide 200 µg plus formoterol 6 µg DPI","slug":"budesonide-200-g-plus-formoterol-6-g-dpi","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"Budesonide extrafine pMDI","genericName":"Budesonide extrafine pMDI","slug":"budesonide-extrafine-pmdi","indication":"Maintenance treatment of asthma","status":"phase_2"},{"name":"CHF 1535","genericName":"CHF 1535","slug":"chf-1535","indication":"Chronic obstructive pulmonary disease (COPD) maintenance therapy","status":"phase_3"},{"name":"CHF 1535 100/6 pMDI 2 months","genericName":"CHF 1535 100/6 pMDI 2 months","slug":"chf-1535-100-6-pmdi-2-months","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"CHF 1535 200/6 µg","genericName":"CHF 1535 200/6 µg","slug":"chf-1535-200-6-g","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"CHF 1535 50/6µg","genericName":"CHF 1535 50/6µg","slug":"chf-1535-50-6-g","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"CHF 4226 pMDI","genericName":"CHF 4226 pMDI","slug":"chf-4226-pmdi","indication":"Chronic obstructive pulmonary disease (COPD) maintenance treatment","status":"phase_2"},{"name":"CHF 5993 100/6/12.5 µg","genericName":"CHF 5993 100/6/12.5 µg","slug":"chf-5993-100-6-12-5-g","indication":"Chronic obstructive pulmonary disease (COPD) maintenance therapy","status":"phase_3"},{"name":"CHF 5993 200/6/12.5 µg","genericName":"CHF 5993 200/6/12.5 µg","slug":"chf-5993-200-6-12-5-g","indication":"Chronic obstructive pulmonary disease (COPD) maintenance therapy","status":"phase_3"},{"name":"CHF 5993 DPI","genericName":"CHF 5993 DPI","slug":"chf-5993-dpi","indication":"Chronic obstructive pulmonary disease (COPD)","status":"phase_2"},{"name":"CHF 718 pMDI","genericName":"CHF 718 pMDI","slug":"chf-718-pmdi","indication":"Maintenance treatment of asthma","status":"phase_2"},{"name":"CHF1535","genericName":"CHF1535","slug":"chf1535","indication":"Asthma maintenance and reliever therapy","status":"marketed"},{"name":"CHF1535 200/6 µg pMDI","genericName":"CHF1535 200/6 µg pMDI","slug":"chf1535-200-6-g-pmdi","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"CHF1535 NEXT DPI","genericName":"CHF1535 NEXT DPI","slug":"chf1535-next-dpi","indication":"Chronic obstructive pulmonary disease (COPD) maintenance treatment","status":"phase_2"},{"name":"CHF1535 NEXThaler","genericName":"CHF1535 NEXThaler","slug":"chf1535-nexthaler","indication":"Chronic obstructive pulmonary disease (COPD)","status":"phase_2"},{"name":"CHF1535 pMDI","genericName":"CHF1535 pMDI","slug":"chf1535-pmdi","indication":"Maintenance and relief of asthma symptoms","status":"phase_2"},{"name":"CHF5993 pMDI","genericName":"CHF5993 pMDI","slug":"chf5993-pmdi","indication":"Maintenance treatment of asthma","status":"phase_2"},{"name":"Clenil® Modulite® via AeroChamber Plus™","genericName":"Clenil® Modulite® via AeroChamber Plus™","slug":"clenil-modulite-via-aerochamber-plus","indication":"Maintenance and relief of asthma symptoms","status":"phase_2"},{"name":"FlF/VI + Tiotropium","genericName":"FlF/VI + Tiotropium","slug":"flf-vi-tiotropium","indication":"Chronic obstructive pulmonary disease (COPD) maintenance therapy","status":"phase_3"},{"name":"Formoterol 12 µg DPI","genericName":"Formoterol 12 µg DPI","slug":"formoterol-12-g-dpi","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"Formoterol Inhalation Solution","genericName":"Formoterol Inhalation Solution","slug":"formoterol-inhalation-solution","indication":"Chronic obstructive pulmonary disease (COPD)","status":"marketed"},{"name":"Foster BDP/Formoterol","genericName":"Foster BDP/Formoterol","slug":"foster-bdp-formoterol","indication":"Asthma maintenance therapy","status":"marketed"},{"name":"Glycopyrrolate + Formoterol","genericName":"Glycopyrrolate + Formoterol","slug":"glycopyrrolate-formoterol","indication":"Chronic obstructive pulmonary disease (COPD) maintenance therapy","status":"marketed"},{"name":"Seretide® Accuhaler® 250/50 µg/actuation","genericName":"Seretide® Accuhaler® 250/50 µg/actuation","slug":"seretide-accuhaler-250-50-g-actuation","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"beclomethasone/salbutamol combination","genericName":"beclomethasone/salbutamol combination","slug":"beclomethasone-salbutamol-combination","indication":"Maintenance and relief of asthma symptoms","status":"phase_3"},{"name":"budesonide plus formoterol combination","genericName":"budesonide plus formoterol combination","slug":"budesonide-plus-formoterol-combination","indication":"Maintenance and control of asthma symptoms","status":"phase_3"},{"name":"umeclidinium bromide and vilanterol trifenatate","genericName":"umeclidinium bromide and vilanterol trifenatate","slug":"umeclidinium-bromide-and-vilanterol-trifenatate","indication":"Chronic obstructive pulmonary disease (COPD) maintenance treatment","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":13,"colorKey":"immunology","drugs":[{"name":"CHF 5259 12.5 µg","genericName":"CHF 5259 12.5 µg","slug":"chf-5259-12-5-g","indication":"Other","status":"phase_2"},{"name":"CHF5259","genericName":"CHF5259","slug":"chf5259","indication":"Other","status":"phase_1"},{"name":"CHF718 pMDI with HFA-134a","genericName":"CHF718 pMDI with HFA-134a","slug":"chf718-pmdi-with-hfa-134a","indication":"Other","status":"phase_2"},{"name":"Oleogel-S10","genericName":"Oleogel-S10","slug":"oleogel-s10","indication":"Acute wounds (cuts, abrasions, minor surgical wounds)","status":"phase_3"},{"name":"CHF 1535 Next DPI","genericName":"CHF 1535 Next DPI","slug":"chf-1535-next-dpi","indication":"Cystic fibrosis","status":"phase_2"},{"name":"CHF 1535 pMDI","genericName":"CHF 1535 pMDI","slug":"chf-1535-pmdi","indication":"Other","status":"phase_2"},{"name":"CHF 5188 pMDI","genericName":"CHF 5188 pMDI","slug":"chf-5188-pmdi","indication":"Other","status":"phase_2"},{"name":"CHF5633","genericName":"CHF5633","slug":"chf5633","indication":"Treatment of cystic fibrosis","status":"phase_2"},{"name":"CHF5993","genericName":"CHF5993","slug":"chf5993","indication":"Other","status":"marketed"},{"name":"CHF6001","genericName":"CHF6001","slug":"chf6001","indication":"Other","status":"phase_2"},{"name":"Clenil® Modulite® via Volumatic™ spacer","genericName":"Clenil® Modulite® via Volumatic™ spacer","slug":"clenil-modulite-via-volumatic-spacer","indication":"Other","status":"phase_2"},{"name":"Foster","genericName":"Foster","slug":"foster","indication":"Other","status":"marketed"},{"name":"elapegademase-lvlr","genericName":"elapegademase-lvlr","slug":"elapegademase-lvlr","indication":"Other","status":"marketed"}]},{"name":"Rare Disease","slug":"rare-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Elfabrio","genericName":"PEGUNIGALSIDASE ALFA","slug":"pegunigalsidase-alfa","indication":"Fabry's disease","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"CHF 5259","genericName":"CHF 5259","slug":"chf-5259","indication":"Atrial fibrillation for stroke prevention","status":"phase_2"}]}],"pipeline":[{"name":"Poractant alfa (Curosurf®)","genericName":"Poractant alfa (Curosurf®)","slug":"poractant-alfa-curosurf","phase":"marketed","mechanism":"Poractant alfa is a natural pulmonary surfactant that reduces surface tension in the lungs and restores normal respiratory function in neonates with respiratory distress syndrome.","indications":["Respiratory distress syndrome (RDS) in premature infants","Meconium aspiration syndrome (MAS) in neonates"],"catalyst":""},{"name":"Atimos®","genericName":"Atimos®","slug":"atimos","phase":"marketed","mechanism":"Atimos is a tiotropium bromide inhalation powder that acts as a long-acting anticholinergic (muscarinic antagonist) to relax airway smooth muscle and improve airflow in chronic obstructive pulmonary disease.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"Beclomethasone (BDP)","genericName":"Beclomethasone (BDP)","slug":"beclomethasone-bdp","phase":"phase_3","mechanism":"Beclomethasone is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors in the lungs.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"CHF 1535 100/6 NEXT DPI® 2 months","genericName":"CHF 1535 100/6 NEXT DPI® 2 months","slug":"chf-1535-100-6-next-dpi-2-months","phase":"phase_3","mechanism":"CHF 1535 is a fixed-dose combination of beclomethasone dipropionate and formoterol fumarate delivered via a dry powder inhaler for maintenance treatment of asthma and COPD.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"CHF 1535 100/6 µg","genericName":"CHF 1535 100/6 µg","slug":"chf-1535-100-6-g","phase":"phase_3","mechanism":"CHF 1535 is a fixed-dose combination inhaled corticosteroid and long-acting beta-2 agonist that reduces airway inflammation and improves bronchodilation in respiratory disease.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"CHF 5259 12.5 µg","genericName":"CHF 5259 12.5 µg","slug":"chf-5259-12-5-g","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CHF5259","genericName":"CHF5259","slug":"chf5259","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CHF5993 pMDI with HFA-134a","genericName":"CHF5993 pMDI with HFA-134a","slug":"chf5993-pmdi-with-hfa-134a","phase":"phase_2","mechanism":"CHF5993 pMDI with HFA-134a is a pressurized metered-dose inhaler formulation of a corticosteroid.","indications":["Maintenance treatment of asthma","Maintenance treatment of COPD"],"catalyst":""},{"name":"CHF6001 DPI","genericName":"CHF6001 DPI","slug":"chf6001-dpi","phase":"phase_2","mechanism":"CHF6001 DPI is a dry powder inhaler formulation of a long-acting muscarinic antagonist.","indications":["Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"CHF718 pMDI with HFA-134a","genericName":"CHF718 pMDI with HFA-134a","slug":"chf718-pmdi-with-hfa-134a","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Elfabrio","genericName":"PEGUNIGALSIDASE ALFA","slug":"pegunigalsidase-alfa","phase":"marketed","mechanism":"Elfabrio works by reducing the accumulation of a specific lipid in the body.","indications":["Fabry's disease"],"catalyst":""},{"name":"Fluticasone plus salmeterol fixed combination","genericName":"Fluticasone plus salmeterol fixed combination","slug":"fluticasone-plus-salmeterol-fixed-combination","phase":"phase_3","mechanism":"Fluticasone (a corticosteroid) reduces airway inflammation while salmeterol (a long-acting beta-2 agonist) relaxes airway smooth muscle to improve breathing.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"Formoterol powder 12 µg/unit dose","genericName":"Formoterol powder 12 µg/unit dose","slug":"formoterol-powder-12-g-unit-dose","phase":"phase_3","mechanism":"Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing bronchodilation and improved airflow.","indications":["Chronic obstructive pulmonary disease (COPD)","Asthma (maintenance therapy)"],"catalyst":""},{"name":"Foster® NEXThaler® 100/6 µg/unit dose","genericName":"Foster® NEXThaler® 100/6 µg/unit dose","slug":"foster-nexthaler-100-6-g-unit-dose","phase":"phase_3","mechanism":"Foster NEXThaler combines beclomethasone dipropionate (an inhaled corticosteroid) and formoterol (a long-acting beta-2 agonist) to reduce airway inflammation and improve bronchial smooth muscle relaxation in asthma and COPD.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"Oleogel-S10","genericName":"Oleogel-S10","slug":"oleogel-s10","phase":"phase_3","mechanism":"Oleogel-S10 is a topical oleogel formulation containing birch bark extract that promotes wound healing and tissue repair through anti-inflammatory and antimicrobial properties.","indications":["Acute wounds (cuts, abrasions, minor surgical wounds)","Chronic wounds and ulcers"],"catalyst":""},{"name":"Seretide Accuhaler® 500/50 µg/actuation","genericName":"Seretide Accuhaler® 500/50 µg/actuation","slug":"seretide-accuhaler-500-50-g-actuation","phase":"phase_3","mechanism":"Seretide combines a long-acting beta-2 agonist (salmeterol) and an inhaled corticosteroid (fluticasone propionate) to relax airway smooth muscle and reduce airway inflammation.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"BDP DPI 2 months","genericName":"BDP DPI 2 months","slug":"bdp-dpi-2-months","phase":"phase_3","mechanism":"BDP (beclomethasone dipropionate) is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in the lungs.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"BDP DPI and formoterol DPI","genericName":"BDP DPI and formoterol DPI","slug":"bdp-dpi-and-formoterol-dpi","phase":"phase_2","mechanism":"This combination inhaler delivers beclomethasone dipropionate (a corticosteroid) and formoterol (a long-acting beta-2 agonist) to reduce airway inflammation and improve bronchial smooth muscle relaxation in obstructive airway diseases.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"BDP HFA 100 µg pMDI","genericName":"BDP HFA 100 µg pMDI","slug":"bdp-hfa-100-g-pmdi","phase":"phase_3","mechanism":"BDP (beclomethasone dipropionate) is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in the lungs.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"BDP/FF + Tiotropium","genericName":"BDP/FF + Tiotropium","slug":"bdp-ff-tiotropium","phase":"phase_3","mechanism":"BDP/FF (beclomethasone/formoterol) is an inhaled corticosteroid plus long-acting beta-2 agonist combination that reduces airway inflammation and bronchospasm, while tiotropium is a long-acting muscarinic antagonist that provides sustained bronchodilation.","indications":["Asthma (maintenance therapy)","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"BDP/FF/GB","genericName":"BDP/FF/GB","slug":"bdp-ff-gb","phase":"phase_3","mechanism":"BDP/FF/GB is a triple-combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist that reduces airway inflammation and improves bronchodilation through multiple pathways.","indications":["Chronic obstructive pulmonary disease (COPD)","Asthma (potential indication under investigation)"],"catalyst":""},{"name":"BDP/Formoterol Next DPI","genericName":"BDP/Formoterol Next DPI","slug":"bdp-formoterol-next-dpi","phase":"phase_3","mechanism":"BDP/Formoterol combines an inhaled corticosteroid (beclomethasone dipropionate) with a long-acting beta-2 agonist (formoterol) to reduce airway inflammation and improve bronchial smooth muscle relaxation.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"BDP/salbutamol CFC pMDI","genericName":"BDP/salbutamol CFC pMDI","slug":"bdp-salbutamol-cfc-pmdi","phase":"phase_3","mechanism":"BDP/salbutamol is a combination inhaler that reduces airway inflammation via corticosteroid action while providing rapid bronchodilation through beta-2 agonist stimulation.","indications":["Asthma maintenance and reliever therapy","Chronic obstructive pulmonary disease (COPD) with reversible airflow obstruction"],"catalyst":""},{"name":"BDP/salbutamol HFA pMDI","genericName":"BDP/salbutamol HFA pMDI","slug":"bdp-salbutamol-hfa-pmdi","phase":"phase_3","mechanism":"BDP/salbutamol is a combination inhaler that reduces airway inflammation via corticosteroid action while providing rapid bronchodilation through beta-2 agonist stimulation.","indications":["Asthma maintenance and reliever therapy","Chronic obstructive pulmonary disease (COPD) with reversible airflow obstruction"],"catalyst":""},{"name":"Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium","genericName":"Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium","slug":"beclometasone-dipropionate-formoterol-fumarate-glycopyrronium","phase":"phase_3","mechanism":"This triple-combination inhaler delivers a corticosteroid to reduce airway inflammation, a long-acting beta-2 agonist to relax airway smooth muscle, and an anticholinergic to further dilate airways.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance therapy","Asthma maintenance therapy (in select populations)"],"catalyst":""},{"name":"Beclometasone/Formoterol","genericName":"Beclometasone/Formoterol","slug":"beclometasone-formoterol","phase":"marketed","mechanism":"Beclometasone is a corticosteroid that reduces airway inflammation, while formoterol is a long-acting beta-2 agonist that relaxes bronchial smooth muscle, together providing anti-inflammatory and bronchodilatory effects.","indications":["Asthma maintenance and reliever therapy","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"Beclometasone/Formoterol/Glycopyrrolate","genericName":"Beclometasone/Formoterol/Glycopyrrolate","slug":"beclometasone-formoterol-glycopyrrolate","phase":"phase_3","mechanism":"This triple-combination inhaler delivers a corticosteroid (beclometasone) to reduce airway inflammation, a long-acting beta-2 agonist (formoterol) to dilate airways, and an anticholinergic (glycopyrrolate) to further relax airway smooth muscle.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance treatment"],"catalyst":""},{"name":"Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium","genericName":"Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium","slug":"beclomethasone-dipropionate-formoterol-fumarate-glycopyrronium","phase":"phase_3","mechanism":"This triple-combination inhaler delivers a corticosteroid to reduce airway inflammation, a long-acting beta-2 agonist to relax airway smooth muscle, and an anticholinergic to further dilate airways.","indications":["Maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults"],"catalyst":""},{"name":"Beclomethasone dipropionate/Salbutamol combination","genericName":"Beclomethasone dipropionate/Salbutamol combination","slug":"beclomethasone-dipropionate-salbutamol-combination","phase":"phase_3","mechanism":"This combination inhaler delivers a corticosteroid to reduce airway inflammation and a short-acting beta-2 agonist to rapidly relax bronchial smooth muscle.","indications":["Asthma maintenance and reliever therapy","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"Beclomethasone plus formoterol fixed combination","genericName":"Beclomethasone plus formoterol fixed combination","slug":"beclomethasone-plus-formoterol-fixed-combination","phase":"phase_3","mechanism":"Beclomethasone (a corticosteroid) reduces airway inflammation while formoterol (a long-acting beta-2 agonist) relaxes airway smooth muscle to improve breathing.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"Budesonide 200 µg plus formoterol 6 µg DPI","genericName":"Budesonide 200 µg plus formoterol 6 µg DPI","slug":"budesonide-200-g-plus-formoterol-6-g-dpi","phase":"phase_3","mechanism":"Budesonide reduces airway inflammation while formoterol relaxes airway smooth muscle, together improving airflow and reducing asthma/COPD symptoms.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"Budesonide extrafine pMDI","genericName":"Budesonide extrafine pMDI","slug":"budesonide-extrafine-pmdi","phase":"phase_2","mechanism":"Budesonide extrafine pMDI is a corticosteroid that works by reducing inflammation in the lungs.","indications":["Maintenance treatment of asthma","Maintenance treatment of COPD"],"catalyst":""},{"name":"CHF 1535","genericName":"CHF 1535","slug":"chf-1535","phase":"phase_3","mechanism":"CHF 1535 is a dual bronchodilator that combines a long-acting beta-2 agonist with a long-acting muscarinic antagonist to improve airway function in chronic obstructive pulmonary disease.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"CHF 1535 100/6 pMDI 2 months","genericName":"CHF 1535 100/6 pMDI 2 months","slug":"chf-1535-100-6-pmdi-2-months","phase":"phase_3","mechanism":"CHF 1535 is a fixed-dose combination inhaled corticosteroid and long-acting beta-2 agonist that reduces airway inflammation and improves bronchodilation in respiratory disease.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"CHF 1535 200/6 µg","genericName":"CHF 1535 200/6 µg","slug":"chf-1535-200-6-g","phase":"phase_3","mechanism":"CHF 1535 is a fixed-dose combination inhaled corticosteroid and long-acting beta-2 agonist that reduces airway inflammation and improves bronchodilation in respiratory disease.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"CHF 1535 50/6µg","genericName":"CHF 1535 50/6µg","slug":"chf-1535-50-6-g","phase":"phase_3","mechanism":"CHF 1535 is a fixed-dose combination inhaled corticosteroid and long-acting beta-2 agonist that reduces airway inflammation and improves bronchodilation in respiratory disease.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"CHF 1535 Next DPI","genericName":"CHF 1535 Next DPI","slug":"chf-1535-next-dpi","phase":"phase_2","mechanism":"CHF 1535 Next DPI is a dry powder inhaler for the treatment of cystic fibrosis.","indications":["Cystic fibrosis"],"catalyst":""},{"name":"CHF 1535 pMDI","genericName":"CHF 1535 pMDI","slug":"chf-1535-pmdi","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CHF 4226 pMDI","genericName":"CHF 4226 pMDI","slug":"chf-4226-pmdi","phase":"phase_2","mechanism":"CHF 4226 is an inhaled dual bronchodilator combining a long-acting beta-2 agonist and long-acting muscarinic antagonist for maintenance treatment of chronic obstructive pulmonary disease.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance treatment"],"catalyst":""},{"name":"CHF 5188 pMDI","genericName":"CHF 5188 pMDI","slug":"chf-5188-pmdi","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CHF 5259","genericName":"CHF 5259","slug":"chf-5259","phase":"phase_2","mechanism":"CHF 5259 is a small molecule drug that acts as a selective inhibitor of the sodium-activated potassium channel, KCNN4.","indications":["Atrial fibrillation for stroke prevention"],"catalyst":""},{"name":"CHF 5993 100/6/12.5 µg","genericName":"CHF 5993 100/6/12.5 µg","slug":"chf-5993-100-6-12-5-g","phase":"phase_3","mechanism":"CHF 5993 is a triple-combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist that reduces airway inflammation and improves bronchodilation through multiple pathways.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance therapy","Asthma maintenance therapy (potential)"],"catalyst":""},{"name":"CHF 5993 200/6/12.5 µg","genericName":"CHF 5993 200/6/12.5 µg","slug":"chf-5993-200-6-12-5-g","phase":"phase_3","mechanism":"CHF 5993 is a triple-combination inhaled therapy that combines a long-acting beta-2 agonist, long-acting muscarinic antagonist, and inhaled corticosteroid to improve airway function and reduce inflammation in chronic obstructive pulmonary disease.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"CHF 5993 DPI","genericName":"CHF 5993 DPI","slug":"chf-5993-dpi","phase":"phase_2","mechanism":"CHF 5993 DPI is a dry powder inhaler formulation of a specific drug.","indications":["Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"CHF 718 pMDI","genericName":"CHF 718 pMDI","slug":"chf-718-pmdi","phase":"phase_2","mechanism":"CHF 718 pMDI is a corticosteroid used to reduce inflammation in the airways.","indications":["Maintenance treatment of asthma","Treatment of chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"CHF1535","genericName":"CHF1535","slug":"chf1535","phase":"marketed","mechanism":"CHF1535 is a fixed-dose combination of beclomethasone dipropionate and formoterol fumarate that reduces airway inflammation and provides bronchodilation for respiratory disease management.","indications":["Asthma maintenance and reliever therapy","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"CHF1535 200/6 µg pMDI","genericName":"CHF1535 200/6 µg pMDI","slug":"chf1535-200-6-g-pmdi","phase":"phase_3","mechanism":"CHF1535 is a fixed-dose combination of beclomethasone dipropionate (ICS) and formoterol (LABA) that reduces airway inflammation and improves bronchial smooth muscle relaxation.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"CHF1535 NEXT DPI","genericName":"CHF1535 NEXT DPI","slug":"chf1535-next-dpi","phase":"phase_2","mechanism":"CHF1535 is a dual bronchodilator combining an inhaled corticosteroid with a long-acting beta-2 agonist and long-acting muscarinic antagonist for maintenance treatment of chronic obstructive pulmonary disease.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance treatment"],"catalyst":""},{"name":"CHF1535 NEXThaler","genericName":"CHF1535 NEXThaler","slug":"chf1535-nexthaler","phase":"phase_2","mechanism":"CHF1535 NEXThaler is a dry powder inhaler delivering a fixed dose of a combination of fluticasone furoate and umeclidinium","indications":["Chronic obstructive pulmonary disease (COPD)","Asthma"],"catalyst":""},{"name":"CHF1535 pMDI","genericName":"CHF1535 pMDI","slug":"chf1535-pmdi","phase":"phase_2","mechanism":"CHF1535 pMDI is a corticosteroid inhalation powder.","indications":["Maintenance and relief of asthma symptoms","Maintenance treatment of COPD symptoms"],"catalyst":""},{"name":"CHF5633","genericName":"CHF5633","slug":"chf5633","phase":"phase_2","mechanism":"CHF5633 is a small molecule in development for the treatment of cystic fibrosis.","indications":["Treatment of cystic fibrosis"],"catalyst":""},{"name":"CHF5993","genericName":"CHF5993","slug":"chf5993","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CHF5993 pMDI","genericName":"CHF5993 pMDI","slug":"chf5993-pmdi","phase":"phase_2","mechanism":"CHF5993 pMDI is a corticosteroid inhalation powder for the maintenance treatment of asthma and the treatment of chronic obstructive pulmonary disease (COPD).","indications":["Maintenance treatment of asthma","Treatment of chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"CHF6001","genericName":"CHF6001","slug":"chf6001","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Clenil® Modulite® via AeroChamber Plus™","genericName":"Clenil® Modulite® via AeroChamber Plus™","slug":"clenil-modulite-via-aerochamber-plus","phase":"phase_2","mechanism":"Clenil Modulite is a corticosteroid that reduces inflammation in the airways.","indications":["Maintenance and relief of asthma symptoms","Maintenance treatment of chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"Clenil® Modulite® via Volumatic™ spacer","genericName":"Clenil® Modulite® via Volumatic™ spacer","slug":"clenil-modulite-via-volumatic-spacer","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"FlF/VI + Tiotropium","genericName":"FlF/VI + Tiotropium","slug":"flf-vi-tiotropium","phase":"phase_3","mechanism":"FlF/VI is a fixed-dose combination of fluticasone furoate and vilanterol (long-acting beta-2 agonist and inhaled corticosteroid) combined with tiotropium (long-acting muscarinic antagonist) to provide multi-mechanism bronchodilation and anti-inflammatory effects in chronic obstructive pulmonary disease.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"Formoterol 12 µg DPI","genericName":"Formoterol 12 µg DPI","slug":"formoterol-12-g-dpi","phase":"phase_3","mechanism":"Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"Formoterol Inhalation Solution","genericName":"Formoterol Inhalation Solution","slug":"formoterol-inhalation-solution","phase":"marketed","mechanism":"Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.","indications":["Chronic obstructive pulmonary disease (COPD)","Asthma (maintenance therapy)"],"catalyst":""},{"name":"Foster","genericName":"Foster","slug":"foster","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Foster BDP/Formoterol","genericName":"Foster BDP/Formoterol","slug":"foster-bdp-formoterol","phase":"marketed","mechanism":"Foster combines beclomethasone dipropionate (a corticosteroid) and formoterol (a long-acting beta-2 agonist) to reduce airway inflammation and dilate airways in asthma and COPD.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"Glycopyrrolate + Formoterol","genericName":"Glycopyrrolate + Formoterol","slug":"glycopyrrolate-formoterol","phase":"marketed","mechanism":"Glycopyrrolate is an anticholinergic agent that blocks muscarinic receptors to reduce airway secretions and bronchoconstriction, while formoterol is a long-acting beta-2 agonist that relaxes airway smooth muscle.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"Seretide® Accuhaler® 250/50 µg/actuation","genericName":"Seretide® Accuhaler® 250/50 µg/actuation","slug":"seretide-accuhaler-250-50-g-actuation","phase":"phase_3","mechanism":"Seretide combines a long-acting beta-2 agonist (salmeterol) and an inhaled corticosteroid (fluticasone propionate) to relax airway smooth muscle and reduce airway inflammation.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"beclomethasone/salbutamol combination","genericName":"beclomethasone/salbutamol combination","slug":"beclomethasone-salbutamol-combination","phase":"phase_3","mechanism":"Beclomethasone is a corticosteroid that reduces inflammation, while salbutamol is a beta-2 adrenergic receptor agonist that relaxes airway smooth muscle.","indications":["Maintenance and relief of asthma symptoms","Maintenance and relief of chronic obstructive pulmonary disease (COPD) symptoms"],"catalyst":""},{"name":"budesonide plus formoterol combination","genericName":"budesonide plus formoterol combination","slug":"budesonide-plus-formoterol-combination","phase":"phase_3","mechanism":"Budesonide is a corticosteroid that reduces inflammation, while formoterol is a long-acting beta2-adrenergic receptor agonist that relaxes airway muscles.","indications":["Maintenance and control of asthma symptoms","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"elapegademase-lvlr","genericName":"elapegademase-lvlr","slug":"elapegademase-lvlr","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"umeclidinium bromide and vilanterol trifenatate","genericName":"umeclidinium bromide and vilanterol trifenatate","slug":"umeclidinium-bromide-and-vilanterol-trifenatate","phase":"marketed","mechanism":"Umeclidinium is a long-acting muscarinic antagonist and vilanterol is a long-acting beta-2 agonist that together relax airway smooth muscle and improve airflow in chronic obstructive pulmonary disease.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance treatment"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0AJBVV95cUxPTWpXc3VzY3BHVkgtSzBYbE4zc2Rkenc4ZGNYUUZCenVDaEVXdGtYT1pEVWlsWjNmQnplMjNPQjdsaVRhOFdQUDN1eUdUTFQwZUxfOUIwa2NZdFJhZk5lQXZ0ZWpmQzkwY3lLb1dtSnQ2dGlWamJ2NTFhckFreFZNbmtyLXJ2T3lPeG0yMENQOFgxdEhobklMU2VHOVBLYUNyX01iVjRyOVdRZTM2WDB6MncwUk96aUM2TElVRmVDSWFpaTBIU1pXQWJWNUJCcXlsTHBwYmJXdUNDYVFPT09TeVBEaW1HZ0xqMG1MdlgxcF9YTVBRVEIyR3d3anRnTUptcGhsQktRazlzNk9HTmtTV2ZNMGNxOEw3QTR6QThFbDZUazBOekJlRlRmV3Z0b2h4ckdnYnlqMDFvU25rVVdRV1ZTaTFJVl9aZFdzOUEyM3M?oc=5","date":"2026-04-08","type":"pipeline","source":"Barchart.com","summary":"COPD Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Genentech, GlaxoSmithKline, Verona Pharma, Regeneron Pharma, Sanofi, MedImmune, EpiEndo Pharma, Tetherex Pharma, AstraZene","headline":"COPD Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Genentech, GlaxoSmithKline, Verona Pharma,","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxQR2hMczZSNm9ka1BJdWgtbEQxSlh4MS1oNUt1Z0tvdEVWT0FMalk4Y25OQjJEb1hKUFRuUHRZblB1ZzdJSUMtZHhZMTBQTVVtNS1uSzdyUVh3SU4zOS1JMEZfcnFVTm5oY1c2WGRfaXdYSGZXRTgtdmRieWhtMWlOeFNMOFN3WFFyUGNQLUhEcXh4a0JtZVlKLTFoVUxtNjVubmRZVkEwcnh3MHVyM0d4Z3lBRER3Yy1tZGIzaFdkbGV1VE5MS0Z1NmhFNW8xSWNnUzdSekUwUjdfWkZMTUc3UkxOVWlhaktYeFVkVFlsemJqeDFUbU05c0hzLTRTODN1dzdQanpRSmpSazNOZHdWMzZB?oc=5","date":"2025-08-25","type":"pipeline","source":"globenewswire.com","summary":"Non-cystic Fibrosis Bronchiectasis Market Ready to Shift Gears with the Entry of First DPP1 Blocker | DelveInsight - globenewswire.com","headline":"Non-cystic Fibrosis Bronchiectasis Market Ready to Shift Gears with the Entry of First DPP1 Blocker | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5XdVZNOFo3NG9zZTA2UnRpUG9FMHF6QlZUTXZ0bW16T3FiM2RoVEVRRnZkdVJTQWFsRVBBQTl5VE5LR1dDQWY1TGNUYzRiWTJKdWlV?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"AMYT Stock Price, News & Analysis - Stock Titan","headline":"AMYT Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPOEhBWVNJdl9JRDlEYXo4ZHNOa0dqZUxfMFU4aFhoeE9wWTc5WUxqWW54WEpnb3NWN0djUjFYbGxVYm5KMXdWRTVZaXlzUnVkUTV5NXZHaUV4VmdBTEhrNmczakdleExBQTI3a3JRMHljend2dW1Qc09TUTN0cXhNWTJ4Z2p4TGVGc3puY2Y2SzBWTzVQ?oc=5","date":"2024-10-15","type":"pipeline","source":"PharmTech.com","summary":"Chiesi Launches Biotech Center of Excellence in Parma, Italy - PharmTech.com","headline":"Chiesi Launches Biotech Center of Excellence in Parma, Italy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTE9oTTRaN2pQWkJ2WG9JamRBRXlPeC00S3BZRVVBZHJTczhVZklDRllnQmhXcGU5Q25FSmFaQ3hXOHBNbUZzd0FvMmlxVE43OWxiSkJtcm9NTHAxTDNwNUo0WDVFbzJDMXV4TkZ5M18xM3U?oc=5","date":"2024-09-06","type":"earnings","source":"Arup","summary":"Chiesi Farmaceutici Headquarters - Arup","headline":"Chiesi Farmaceutici Headquarters","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxOMTl1YjlHTE9jaEppcmtnN2V3NjVGWmFSSDhaUTl4QWhsQ3pvclNDN3VrbDhSMjdSMEV5MVkwU2VqOVJjYjBLcWlkTTZlbzlTNmFiVW4wM3c3VTdHdTByeXBzS01saEhJMFgwLTh5N09zSE9VSGZrUmpIb3NkZEhJTW13Xy1UMnNZdmI1a2Mtek1iUFNONmZYS19Ka0xsMHByXzJYMUxmdFBURVJjZVFHaGkwQkgwempaWjRQS1hIQUFrajZHa3JzMHZYUTJjVE0?oc=5","date":"2024-05-06","type":"pipeline","source":"reuters.com","summary":"Gossamer Bio and Chiesi Group to collaborate in therapy for lung condition - reuters.com","headline":"Gossamer Bio and Chiesi Group to collaborate in therapy for lung condition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxPWEVNTkFJTmlfN2VzYzVoMnNneXdxOGRKUVoxbEplbnc0Y1BON2dyUDh5TnJ1RTZKaHRtV3NXeDRDcHA4VGc0RzNBMDNaNkd1eG5fM0lVcTYtS0tuTjJDX2FJUG1LbnpRelpUOVFVOFBDWWVtLU1UU0pudE0zM09wWXI1RGtnRzctUFBPb1dtWlpIdWlIMmJwdGZRc2szQVZjdmJJSU5tNlhsbzhleDNV?oc=5","date":"2023-11-20","type":"deal","source":"Contract Pharma","summary":"Chiesi, Haisco Partner on DPP1 Inhibitor for Respiratory Diseases - Contract Pharma","headline":"Chiesi, Haisco Partner on DPP1 Inhibitor for Respiratory Diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5sYWQ4Ykt4WWdZMEhnRFNnRzZjem1KTWhIbU55MUF4dk9OU0pBYS1vdFU1Rk9Ub1Z5WkxBMG5JbjFaMnNBZGk0NkVPcmpBZHpVZW5BU0ZOSWgtNFEycVlERGxtQkgtck5Kd3RSWXZn?oc=5","date":"2023-07-24","type":"pipeline","source":"KED Global","summary":"Kwangdong to sell exclusively three global rare disease drugs - KED Global","headline":"Kwangdong to sell exclusively three global rare disease drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxOVmVGSEhGMl9nTjk0Nm4zT1g5ZDNGdDVWWFkwbXJodVY0Y0l3bDJNX3dOVVFXVWFIdVVkWEVnRTJEVEpZQTJTSXo4ODdtUUhfRlVDalNJeTM3NkJsV3lYWUpzMzNmMm1CNlItTlJXRXphZU1saGQtMDAyYUNicmRTWGZkV1l5RkV3NGthMkhTU1l2dw?oc=5","date":"2023-01-09","type":"deal","source":"Yahoo Finance","summary":"Italian Privately Held Chiesi Farmaceutici To Acquire Amryt Pharma For $1.25B - Yahoo Finance","headline":"Italian Privately Held Chiesi Farmaceutici To Acquire Amryt Pharma For $1.25B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOV1l3Qzk2bUI0TFRzZ3RFRFJjNndESG00TE51S2xIaWU0UGJyV2RWRGc4TUNmaVhFRklRTWdDYVFSVkMyWXE1N1duRzdpdjVaaUt5bm5aZC1mUXpZZWRDZ1BqX210Zm1tZWVYSnJjbHhWVTNuYnpXVHRiSnFYeFBuRk9udWZFUDlXSTNxTTlUaXhUZHRROGdvQnRXMmJhdw?oc=5","date":"2023-01-09","type":"pipeline","source":"pharmaphorum","summary":"Chiesi expands rare disease portfolio with Amryt Pharma acquisition - pharmaphorum","headline":"Chiesi expands rare disease portfolio with Amryt Pharma acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQamNGcVhobnAwbGtLTmtIVGtpSDIzaUFCSDdBaGZXeVpraWJvUE1fdTlHa0oyYzRza2luNUY1RU9IaTl3X3dUb0ZEM0R4RE9wMEF6QTFHRVQxM1VmazhRc0NXdFlFWUo2QndYZUlabktPZmVjYWNNRHpoOE5CXzJLY0NsalhKTGJDMnlNZHYtUHZiRjFTemRmampFU1ZxX3haWFFYUQ?oc=5","date":"2022-03-14","type":"trial","source":"Fierce Pharma","summary":"Chiesi study aims to quantify economic benefits of rare disease drugs - Fierce Pharma","headline":"Chiesi study aims to quantify economic benefits of rare disease drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOWDhWd05YNHh4RGMwMGMzUGJ5T1BVTnEybGVqV3dKX1d6VDlWTzlLZmlsc1NBNHd4VERTa3NuQ1JFYi1lZVVJQzhjUHh6Nnh5Sk1TV05OWXhGaDJrdWhfa1g3OVdzTFpkNVcwaWtUcnVFTXdsRWJJblNmVGRIOEU3R1dvTWxWRk1EWG50RmVUQU5CbUpicEE?oc=5","date":"2020-02-06","type":"pipeline","source":"BioSpace","summary":"Italian Pharma Company Chiesi Opens Rare Disease Offices in Boston - BioSpace","headline":"Italian Pharma Company Chiesi Opens Rare Disease Offices in Boston","sentiment":"neutral"}],"patents":[],"drugCount":67,"phaseCounts":{"marketed":12,"phase_3":33,"phase_2":21,"phase_1":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}